Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome

被引:88
|
作者
Krejsgaard, T. [1 ,2 ]
Odum, N. [2 ]
Geisler, C.
Wasik, M. A. [3 ]
Woetmann, A. [2 ]
机构
[1] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen N, Denmark
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
cutaneous T-cell lymphoma; Sezary syndrome; immunodeficiency; regulatory T cells; FOXP3; mycosis fungoides; TUMOR-INFILTRATING LYMPHOCYTES; GROWTH-FACTOR-BETA; NF-KAPPA-B; FOXP3; EXPRESSION; FAS-LIGAND; CONSTITUTIVE ACTIVATION; MALIGNANT PROLIFERATION; CD127; LYMPHOMA-CELLS; RECEPTOR;
D O I
10.1038/leu.2011.237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphoma (CTCL) is the term for diseases characterized by primary accumulation of malignant T cells in the skin. Patients with the two predominant clinical forms of CTCL called mycosis fungoides (MF) and Sezary syndrome (SS) characteristically develop severe immunodeficiency during disease progression and consequently patients with advanced disease frequently die of infections and not from the tumor burden. For decades, it has been suspected that the malignant T cells actively drive the evolving immunodeficiency to avoid antitumor immunity, yet, the underlying mechanisms remain unclear. The identification of a subset of highly immunosuppressive regulatory T cells (Tregs) triggered a variety of studies investigating if MF and SS are malignant proliferations of Tregs but seemingly discordant findings have been reported. Here, we review the literature to clarify the role of Tregs in MF and SS and discuss the potential mechanisms driving the immunodeficiency. Leukemia (2012) 26, 424-432; doi:10.1038/leu.2011.237; published online 9 September 2011
引用
收藏
页码:424 / 432
页数:9
相关论文
共 50 条
  • [41] Alemtuzumab in patients with advanced mycosis fungoides and Sezary syndrome
    Beltran-Garate, Brady
    Gomez, Henry
    Lopez, Jose L.
    Borrego, Mildred
    Prieto, Mercedes
    Carrasco-Yalan, Antonio A.
    Huamani, Julia
    Castillo, Jorge
    Da Costa, Osiris
    BLOOD, 2007, 110 (11) : 1003A - 1004A
  • [42] EORTC guidelines for the treatment of Mycosis Fungoides/Sezary Syndrome
    Knobler, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : S11 - S11
  • [43] Quality of life of patients with mycosis fungoides and Sezary syndrome
    Jaeger, Manuel
    Oezistanbullu, Deniz
    Klemke, Claus-Detlev
    Tratzmiller, Sabine
    DERMATOLOGIE, 2022, 73 (10): : 759 - 764
  • [44] SEZARY SYNDROME - LEUKEMIC VARIANT OF MYCOSIS-FUNGOIDES
    LOFFLER, H
    MEYHOFER, W
    LANGE, RH
    EHLERS, G
    REMMELE, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1974, 99 (10) : 429 - 434
  • [45] Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome
    Hoppe, Richard T.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 242 - 243
  • [46] CD164 as an Adjunct Marker for Circulating Abnormal T Cells in Mycosis Fungoides and Sezary Syndrome
    Rawson, Beth
    Maracaja, Danielle
    Mehta, Shashi
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 886 - 887
  • [47] CD164 as an Adjunct Marker for Circulating Abnormal T Cells in Mycosis Fungoides and Sezary Syndrome
    Rawson, Beth
    Maracaja, Danielle
    Mehta, Shashi
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 886 - 887
  • [48] How We Treat Mycosis Fungoides and Sezary Syndrome
    Khan, Niloufer
    Noor, Sarah J.
    Horwitz, Steven
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 573 - 581
  • [49] Morphology of Mycosis Fungoides and Sezary Syndrome in Skin of Color
    Espinosa, Maria L.
    Walker, Christina J.
    Guitart, Joan
    Mhlaba, Julia M.
    CUTIS, 2022, 109 (03): : E3 - E7
  • [50] CHEMOTHERAPY FOR MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
    ROSEN, ST
    FOSS, FM
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995, 9 (05) : 1109 - +